Sight Sciences (NASDAQ:SGHT) PT Lowered to $17.00 at Piper Sandler

Sight Sciences (NASDAQ:SGHTGet Rating) had its price target cut by Piper Sandler from $23.00 to $17.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 152.23% from the company’s previous close.

SGHT has been the topic of a number of other research reports. Citigroup lowered their price objective on Sight Sciences from $39.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. Zacks Investment Research downgraded Sight Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, March 10th. Finally, William Blair started coverage on Sight Sciences in a research report on Thursday, February 3rd. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Sight Sciences currently has an average rating of “Buy” and a consensus price target of $28.40.

NASDAQ:SGHT opened at $6.74 on Wednesday. The stock’s fifty day moving average price is $11.34 and its two-hundred day moving average price is $16.21. Sight Sciences has a 1 year low of $6.25 and a 1 year high of $42.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 20.26 and a current ratio of 20.51.

Sight Sciences (NASDAQ:SGHTGet Rating) last posted its earnings results on Thursday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.05. On average, analysts expect that Sight Sciences will post -1.56 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGHT. KCK LTD. bought a new position in Sight Sciences in the fourth quarter valued at $83,918,000. Millennium Management LLC bought a new position in Sight Sciences in the third quarter valued at $35,800,000. Janus Henderson Group PLC bought a new position in Sight Sciences in the third quarter valued at $32,070,000. RTW Investments LP bought a new position in Sight Sciences in the third quarter valued at $29,144,000. Finally, Alliancebernstein L.P. bought a new position in Sight Sciences in the third quarter valued at $28,324,000. 60.76% of the stock is currently owned by institutional investors and hedge funds.

About Sight Sciences (Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Read More

The Fly logo

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.